| Name | Title | Contact Details |
|---|
In 1990, Nitro Snowboards was founded by Thomas Delago and Sepp Ardelt in Seattle, Washington. Over the last 25 years Nitro has helped grow the sport of snowboarding through its groundbreaking product development, marketing, movies, grass roots events, and global team of world class snowboarders. Today Nitro has grown its product to offer all the essentials needed for having a good time snowboarding and traveling. Nitro´s headquarters are divided all over the world from the Mountains of Oberammergau, to the worlds best snow in Salt Lake City, UT, to the creative beaches of California, all the way up to the Northwest snowboarding destination of Vancouver, British Colombia. For more information visit us at http://www.nitrosnowboards.com or @NITROUSA on Instagram
Forever North Partners (FNP) is a purpose-driven company partnering with high-achieving businesses poised for the next phase of growth. Focused on companies possessing unique, disruptive technologies or services, FNP is dedicated to facilitating your ascent to new heights. FNP services offerings: Investees and Investors: FNP excels in collaborating with dynamic, forward-thinking companies seeking additional investment capital to fuel their growth ambitions. Leveraging its extensive network, FNP identifies investors whose interests align with your companies potential. Operational Excellence Services: Boasting over a century of collective industry experience, FNP applies its proven Market-Driven Application Approach to craft precise positioning and messaging strategies empowering your company to penetrate competitive markets, secure new customers, and drive sales. FNP crafts targeted sales and marketing campaigns complete with compelling collateral, ensuring effective outreach to high-value customers within specific application spaces. FNPs network of key opinion leaders (KOLs) will amplify your corporate messaging to drive top-line growth. Executive Recruiting: FNP understands that success hinges on having the right people in pivotal roles. While adopting the necessary tools for growth is crucial, it is the people who epitomize your values and culture that truly propel your company forward. Leadership, especially, demands exceptional individuals who embody your vision and are committed to realizing your companys mission. FNP has earned a stellar reputation for identifying and securing high-caliber, high-performance executives capable of translating your vision into reality. Regulatory Affairs: Navigating the intricate landscape of the life sciences market demands a profound understanding of ever-changing regulatory compliance issues. Reach regulatory excellence with FNP - Your Trusted Life Sciences Partner. Let FNP guide you on your journey to success.
We offer a broad range of premium mattress types and can personalize anything to your unique specifications. We can even create custom branding to bring your mattress products to life. The FoamTex team will go a step further by offering full-service shipping and logistics solutions so you dont have to worry about anything. Well handle everything from the design and production to the fulfillment.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.